TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05186090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 24-week resistance exercise program
Description: This group will perform a 24-week resistance exercise program. Participants will engage in 180 minutes/week of resistance exercise (3 supervised sessions peer week, 60 min/session). The training will consist of a combination of upper and lower body exercises using elastic bands and participants' body weight as the primary resistance. Exercise load and intensity will be based on the number of repetitions (i.e.,10-12 repetitions), resistance of the elastic bands, in ascending order with seven intensities, and also on the exercises' difficulty (i.e., three levels). The prescribed targeted intensity will reach 70-80% of the participants' maximum rating perceived exertion (i.e., 7-8 RPE).The progression (horizontal) will be standardized according to the execution time and RPE, and individualized according to execution speed and band resistance. Heart rate will be monitored in all sessions. Further, intrinsic motivation before and after session and sleep quality will be registered.
Study: NCT06518473

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin prick test
Description: Skin Prick Test (SPT): Common allergens including pollen, dust mites, Pet dander and mold.~Serum IgE Levels: Total IgE Peripheral blood eosinophil was defined as an eosinophil count ≥ 5%, Quality of Life Assessment: COPD Assessment Test (CAT)
Study: NCT04597411

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 225^Ac-PSMA-617
Description: administered intravenously under the dose escalation schedule

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 225^Ac-PSMA-617
Description: administered intravenously under the dose escalation schedule

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 225^Ac-PSMA-617
Description: administered intravenously under the dose escalation schedule

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68^Ga-PSMA-11
Description: administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68^Ga-PSMA-11
Description: administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68^Ga-PSMA-11
Description: administered intravenously at a dose of 111 - 185 MBq (3 - 5 mCi)
Study: NCT05232136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: OH2: Oncolytic Type 2 Herpes Simplex Virus
Study: NCT06314061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G7 Continuous Glucose Monitoring (CGM) System (G7)
Description: A continuous glucose monitor which through a sensor in the skin registers glucose levels every 5 minutes. Glucose levels are shown by connecting the sensor to a mobile device or the Dexcom G7 Receiver where realtime alerts on deviating glucose levels will be sent.
Study: NCT05711628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT and CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transplant Conditioning
Description: Receive standard preparative chemotherapy regimen

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transplant Conditioning
Description: Receive standard preparative chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Given IV
Study: NCT06427603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: workshops and mobile apps: break sedentary behavior by activity breaks
Study: NCT04982380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live
Description: Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Siliankang simulating tablets
Description: Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
Study: NCT06580951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative Peripheral Nerve Interface
Description: The RPNI portion of the case will consist of blunt dissection of the cut sensory branches of the intercostal nerves at the T3 and/or T4 levels, with creation of a peripheral nerve interface using a small cuff of dissected pectoralis muscle and 3-0 Monocryl suture. The breast reconstruction will otherwise be performed as per standard protocol.
Study: NCT04979390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: SHR-1316 administrated intravenously (IV) at protocol defined dose levels
Study: NCT05972616

Intervention type: BIOLOGICAL
Intervention: Natural Matrix Protein (NMP)
Description: human bone allograft
Study: NCT04975581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allograft Patch
Description: Rotator Cuff repair with Allograft Patch (Graftjacket Now)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allograft Patch
Description: Rotator Cuff repair with Allograft Patch (Graftjacket Now)
Study: NCT05769582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-BK polyomavirus (AntiBKV)
Description: Participants in the study arm will each receive four doses (1,000 mg; 1,000 mg or 500 mg in the dose comparison part) of IMP administered at four-week intervals.~IMP will be administered on Days 1, 29, 57 and 85.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Anti-BK polyomavirus (AntiBKV)
Description: Participants in the study arm will each receive four doses (1,000 mg; 1,000 mg or 500 mg in the dose comparison part) of IMP administered at four-week intervals.~IMP will be administered on Days 1, 29, 57 and 85.
Study: NCT06629623

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04760444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Leader Diabetes Self-Management Support
Description: While the effectiveness of peer-led interventions delivering diabetes-related education and support for short-term clinical, psychosocial, and behavioral improvements is well-established, older Black men in particular are less likely to participate and are at a higher risk of drop-out from these studies. This intervention aims to determine if using older Black men as peer leaders to other older Black men will improve retention rates for this population.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Diabetes Self-Management Education
Description: Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom, Med platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Diabetes Self-Management Education
Description: Participants will attend 10 hours of virtual group diabetes self-management education classes led by a certified diabetes care and education specialist through the online HIPPA compliant Zoom, Med platform.
Study: NCT05046834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold application
Description: Oral paracetamol 10 mg/kg, which is administered as standard 60 minutes before the procedure, will be given to patients who have decided to remove the chest tube by the physician and comply with the limitations of the study. After that, initial pain severity and vital signs of the patient will be recorded using FLACC 15 minutes before the start of the chest tube removal process (1.MEASURE). After this measurement, the cold gel package will be wrapped in gauze and placed directly on the skin, covering the area around the chest tube with a radius of about 5 cm. The cold gel package will remain on the skin surface for about 20 minutes. After 15 minutes, the cold package will be removed and the chest tube will be removed by the doctor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold application until 13.6 C
Description: After measurements, the cold gel package, which rotates with one end open and forms a circle, will be wrapped in gauze and placed directly on the skin in a radius of about 5 cm, covering around the chest tube. 10 of the app. After the minute, the skin temperature will be measured with an infrared thermometer if the heat falls below 13.6 o C, the process will be terminated. If the skin temperature does not fall below 13.6 0 C, the application will continue, the application will be terminated when the heat falls below the specified temperature. After the cold package is removed, the chest tube will be removed by the doctor.
Study: NCT05693805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: The remote delivery Tai Chi protocol that will be developed in this study for Veterans with PTSD and pain will be adapted from a protocol that has been well-tested in previous trials All components of the program derive from the classical Yang-style Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Sessions will last 60 minutes, twice a week for 12 weeks. Experienced instructors will follow the Tai Chi protocol with rigorous quality control procedures. We will provide the patients with printed materials on the Tai Chi program, including Tai Chi principles, practice techniques, and safety precautions. Every session will include: warm up and a review of Tai Chi principles; breathing techniques; meditation with Tai Chi movement; and relaxation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness program
Description: The Wellness intervention that will be developed for this study will consist of 60-minute sessions that meet twice a week for 12 weeks, and will be facilitated by doctoral level psychology staff and/or psychology trainees who will be supervised by staff. The Wellness intervention will be based on the VA Whole Health Program which helps individuals identify and achieve their personal health goals. The Whole Health Program include modules that address physical activity, personal development, healthy eating and drinking, stress management, relationships, personal surroundings, and spirituality. Using the SMART goals model, participants will set health and wellness goals each week. Discussions about ways to address potential barriers will be included in this condition.
Study: NCT06464913

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: With or without chest wall RT
Description: Supraclavicular and infraclavicular lymphatic drainage area radiotherapy with or without chest wall RT
Study: NCT04934553

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amplification of Positivity Training
Description: 12 90-minute, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral Therapy
Description: 12 90-minute, clinician-administered treatment sessions focused on strategies to alter cognitions and behavior related to alcohol use.
Study: NCT06206681

Intervention type: PROCEDURE
Intervention: Ultra-pulsed Carbon Dioxide Laser
Description: Excision of eyelid lesion
Study: NCT05169021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine folic acid 5.8mg+intensive antihypertensive therapy
Description: Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure(SBP\<130mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine folic acid 5.8mg+standard antihypertensive therapy
Description: Amlodipine folic acid tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP:130-140mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine+intensive antihypertensive therapy
Description: Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine+standard antihypertensive therapy
Description: Amlodipine tablet 5.8mg, taken daily, in the morning after waking.~To achieve target blood pressure (SBP: 130-140 mmHg), this study will provide, if needed, concurrent antihypertensive medications. Patients will be asked to discontinue all prior concurrent medications. Recommended treatment options are described below:~1. Add candesartan 4mg;~2. Add indapamide 2.5mg;~3. Increase dose of candesartan to 8mg;~4. Increase dose of amlodipine to 7.5mg-10mg.
Study: NCT05262556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-101 (TQ Formula)
Description: Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab (3mg/kg)
Description: Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab (1mg/kg)
Description: Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.
Study: NCT06382545

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fanta (Pepsi gold) (FPG)
Description: endodontic treatment of posterior teeth with Fanta (Pepsi gold) (FPG)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M3-pro+ Gold (assorted) (MPG)
Description: endodontic treatment of posterior teeth with M3-pro+ Gold (assorted) (MPG) rotary files.
Study: NCT05142228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab-Aooe
Description: Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once every 4weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.
Study: NCT05675631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension training
Description: This group will perform training using suspension devices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: This group will perform training using weights and elastic bands.
Study: NCT06275880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-articular infiltration of PVP Collagen
Description: Intra-articular collagen injection plus physiotherapy program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Patients who received conservative treatment through rehabilitation with a home program for one month
Study: NCT06024499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HY209GEL Active
Description: Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HY209GEL Active
Description: Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06059313

Intervention type: OTHER
Intervention: Submission of the NEO-PI-3 questionnaire
Description: The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

Intervention type: OTHER
Intervention: Submission of the NEO-PI-3 questionnaire
Description: The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

Intervention type: OTHER
Intervention: Submission of the NEO-PI-3 questionnaire
Description: The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

Intervention type: OTHER
Intervention: Submission of the NEO-PI-3 questionnaire
Description: The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).

Intervention type: OTHER
Intervention: Submission of the Interpersonal Reactivity Index questionnaire (IRI)
Description: The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.

Intervention type: OTHER
Intervention: Submission of the Interpersonal Reactivity Index questionnaire (IRI)
Description: The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.

Intervention type: OTHER
Intervention: Submission of the Interpersonal Reactivity Index questionnaire (IRI)
Description: The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.

Intervention type: OTHER
Intervention: Submission of the Interpersonal Reactivity Index questionnaire (IRI)
Description: The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.
Study: NCT05094115

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological Flexibility Training (PFT)
Description: A 2-day workshop lasting approximately 8 hours per day. Day 1: an overview of the training and to describe the posture or stance that prepares one to respond to challenging situations in a psychologically flexible manner.~Day 2: identifies common coping strategies that typically fail or even backfire over the long term and to practice skills that promote psychological flexibility. Experiential exercises will be integrated throughout the training.~Following the PFT, 4 optional, monthly, one-hour booster sessions to supply refresher information.~* An experiential exercise to highlight one or more process/concept that was introduced during the 2-day training.~* Questions from the attendees about applying the concepts in their lives.~* Comments and questions from the booster session facilitators to encourage application of the concepts.
Study: NCT05429255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Bicycle training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exergame Training
Description: Nintendo Wii
Study: NCT05419492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETX101
Description: ETX101 is a non-replicating, recombinant adeno-associated viral vector serotype 9 (rAAV9) comprising a GABAergic regulatory element (reGABA) and an engineered transcription factor that increases transcription of the SCN1A gene (eTFSCN1A). ETX101 is intended as a one-time intracerebroventricular (ICV) administration.
Study: NCT06510296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Mind Body Intervention mobile application
Description: A DMBI mobile application with psychoeducation and skill-building in illness perception, coping, mindfulness, and disease acceptance informed by needs/barriers of Black and Hispanic patients with IBD who have elevated psychological distress and GI professionals caring for IBD patients.